Morgan Stanley raised the firm’s price target on Zimmer Biomet to $125 from $120 and keeps an Equal Weight rating on the shares. A combination of rising 10 year rates and GLP-1 pressures have pushed the valuation of the U.S. MedTech sector down and given the material de-rating the firm is upgrading its Industry View on MedTech to Attractive, the analyst tells investors. Volumes remain in strong shape, capital equipment is looking healthy and the firm sees limited expected impact from GLP-1s, the analyst added in a note on the group in which the firm adjusted a number of price targets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ZBH:
- Zimmer Biomet price target lowered to $140 from $160 at JMP Securities
- Zimmer Biomet management to meet with BTIG
- Zimmer Biomet price target lowered to $149 from $172 at Baird
- Zimmer Biomet price target lowered to $119 from $152 at Wells Fargo
- Zimmer Biomet backs FY23 adjusted EPS view $7.47-$7.57, consensus $7.50